Association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients

Samaneh Ramezani1 · Fatemeh Ezzatifar2,3 · Tahereh Hojjatipour4 · Maryam Hemmatzadeh5 · Arezoo Gowhari Shabgah6 · Jamshid Gholizadeh Navashenaq7 · Saeed Aslani8 · Navid Shomali9 · Mohsen Arabi9 · Farhad Babaie10 · Farhad Jadidi-Niaragh11,12 · Ramin Hosseinzadeh8 · Fahimeh Feizisani13 · Sara Khodayar14 · Roghaiyeh Safari15,16 · Hamed Mohammadi14,17

Received: 30 April 2022 / Accepted: 31 August 2022 / Published online: 1 November 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract
Background  Seemingly, the Matrix metalloproteinases (MMPs) play a role in the etiopathogenesis of coronavirus disease 2019 (COVID-19). Here in this study, we determined the association of MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms with the risk of COVID-19, especially in those with neurological syndrome (NS).
Methods  We enrolled 500 patients with COVID-19 and 500 healthy individuals. To genotype the target SNPs, the Real-time allelic discrimination technique was used. To determine serum levels of MMPs, Enzyme-linked immunosorbent assay (ELISA) was exerted.
Results  The MMP9 gene rs3918242 and MMP3 gene rs3025058 SNP were significantly associated with increased COVID-19 risk and susceptibility to COVID-19 with NS. The serum level of MMP-9 and MMP-3 was significantly higher in COVID-19 cases compared with the healthy controls. Serum MMP-9 and MMP-3 levels were also higher in COVID-19 subjects with NS in comparison to the healthy controls. The polymorphisms in MMP genes were not associated with serum level of MMPs.
Conclusion  MMP9 and MMP3 gene polymorphisms increases the susceptibility to COVID-19 as well as COVID-19 with neurologic syndrome, but they probably have no role in the regulation of serum MMP-9 and MMP-3 levels.

Keywords  Coronavirus disease 2019 · Central nervous system · Matrix metalloproteinases · Genetic polymorphism · Neurological symptoms

Abbreviations
MMPs  Matrix metalloproteinases
COVID-19  Coronavirus disease 2019
ELISA  Enzyme-linked immunosorbent assay
SARS-CoV-2  Severe acute respiratory syndrome coronavirus 2
ACE2  Angiotensin-converting enzyme 2
CNS  Central nervous system
RT-PCR  Reverse-transcriptase–polymerase chain-reaction
CSF  Cerebrospinal fluid
ECM  Extracellular matrix
BBB  Blood-brain barrier
ICAM-1  Intercellular adhesion molecule 1
TNF  Tumor necrosis factor
SNP  Single nucleotide polymorphism
ICU  Intensive care unit
OR  Odds ratios
CI  confidence intervals
HWE  Hardy–Weinberg Equilibrium
SD  Standard deviation
ARDS  Acute respiratory distress syndrome
IL  Interleukin
TMPRSS2  Transmembrane serine protease 2

Extended author information available on the last page of the article
MS  Multiple sclerosis  
MBP  Myelin basic protein

**Introduction**

The recently emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attacks to lungs and several body organs and causes coronavirus disease 2019 (COVID-19). The virus also attacks organs (like heart and kidneys) expressing angiotensin-converting enzyme 2 (ACE2) receptor as the main molecular receptor for S protein of virus [1, 2]. Additionally, neurological manifestations are also reported commonly in patients with COVID-19 [3]. SARS-CoV-2 nucleic acid has been identified by reverse-transcriptase–polymerase chain-reaction (RT-PCR) in the cerebrospinal fluid (CSF) samples of a number of COVID-19 patients [4]. Moreover, virus particles have also been detected in the autopsy samples of brain in a subject [5]. However, it is not clear if the neurological manifestations are due to infection of the Central nervous system (CNS) by SARS-CoV-2 or other possible mechanisms might cause complications related to CNS.

Matrix metalloproteinases (MMPs) are calcium-dependent zinc-containing endopeptidases enzymes that act in the extracellular environment of cells and play a role in degrading extracellular matrix (ECM) and basement membrane by cleaving both matrix and non-matrix proteins. These enzymes are involved in different physiological as well as pathological processes, such as wound healing, morphogenesis, tissue repair and remodeling, inflammation, and angiogenesis [6, 7]. Studies show that MMPs are involved in the facilitation of immune cells infiltration into the CNS through the blood-brain barrier (BBB) [8]. In addition, it was observed that MMP-3 levels are increased in the serum of COVID-19 patients that was correlated with higher levels of inflammatory cytokines [9]. According to a hypothesis, upon entrance of SARS-CoV-2 into human airways, it may pass through the epithelial cells into blood circulation and then infect monocytes. Seemingly, increased permeability of BBB by MMP-9 and enhanced expression of Intercellular adhesion molecule 1 (ICAM-1) on the endothelial cells by Tumor necrosis factor (TNF)-α promotes the migration of infected monocytes to the CNS. Thereupon, monocytes secrete inflammatory mediators in the CNS that leads to injury to neurons and oligodendrocytes [10].

Studies show that the genomic sequences of MMP genes are polymorphic that might be involved in the regulation of MMP gene expression [11-14]. Numerous studies have indicated that single nucleotide polymorphisms (SNPs) in the different MMP genes are associated with human diseases [15], especially infectious diseases [16, 17] and neurodegenerative disorders [18, 19]. Taking all, here we intended to disclose the possible association of MMP9 gene rs3918242, MMP3 gene rs3025058, and MMP2 gene rs243865 polymorphisms with the risk of COVID-19 disease. Moreover, the possible involvement of these polymorphisms in the development of COVID-19 associated neurologic symptoms was evaluated.

**Study participants and methods**

**COVID-19 patients and healthy controls**

In the current case-control study, 500 subjects with COVID-19 and 500 age and gender matched healthy individuals were recruited (Table 1). COVID-19 patients were diagnosed by Real-time PCR for the infection by SARS-CoV-2 by nasopharyngeal swabs and were selected from those who...
referred to the intensive care unit (ICU) of Shahid Rajaee hospital of Karaj, Iran. Patients had severe form of the disease and had respiratory failure and decreased oxygen saturation. The neurologic symptoms of the patients were also determined by a neurologist. Individuals in the control group were negative for the SARS-CoV-2 nucleic acid in nasopharyngeal swabs evaluated by Real-time PCR. Before sampling (10 ml of venous blood), all participants signed written informed forms and the local ethical committee of Alborz University of Medical Science approved the protocol of the study (IR.ABZUMS.REC.1399.340).

DNA extraction and genotyping of polymorphisms

About 10 ml of peripheral blood was obtained from all case and control subjects using EDTA containing venipuncture for DNA extraction as well as tubes for serum isolation. The whole blood samples were stored in -20 °C before extracting DNA. The DNA content from whole blood was isolated by exerting the QIAamp DNA Mini Kit (Qiagen, Germany). The quality and quantity of the extracted DNA samples was determined by optical density (OD) at 260/280 nm ratio by a NanoDrop spectrophotometer system (NanoDrop ND-2000 C Spectrophotometer, Thermo Fisher Scientific, USA). Then, MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms were genotyped by Real-time allelic discrimination method using StepOne-Plus Real-Time PCR device (Applied Biosystems, Foster City, USA) and TaqMan assays (Applied Biosystems, Foster City, USA). The reaction mixture in each well of 96-microwell plates contained 2 µl DNA (20 ng/µl), 5 µl TaqMan Master Mix (containing Taq DNA polymerase and dNTPs), 0.5 µl TaqMan Genotyping Assay Mix (containing primers and probes; Applied Biosystems, Foster City, USA), and distilled water for reaching a total volume of 15 µl. The thermocycling conditions of the PCR reactions were as follow; initial heating for 60 °C for 30 s followed by 95 °C for 10 min, then 40 cycles of amplification in 95 °C for 15 s and 60 °C for 50 s, and ultimately 60 °C for 45 s.

Serum levels of MMPs

Serum samples were isolated from the venous blood of 80 COVID-19 cases as well as 80 healthy controls to measure the concentration of the MMP-9, MMP-3, and MMP-2 using the enzyme linked immunosorbent assay (ELISA) technique. The OD was determined using a commercial kit (Invitrogen, Thermo Fisher Scientific, San Diego, CA, USA) and an ELISA reader device (Tecan Spectra, Austria).

Statistical analysis

The distribution of the alleles and genotypes was represented as frequency and corresponding percentage. The associations between the different genetic models of polymorphisms and risk of COVID-19 were analyzed by Pearson’s chi square ($\chi^2$). To determine the association level, the odds ratios (OR) and corresponding 95% confidence intervals (CI) were calculated.

Genotype distribution of SNPs in the control group was tested to comply with the Hardy–Weinberg Equilibrium (HWE). Exploring for the normality of numeric data distribution was done by the Kolmogorov-Smirnov test. The serum level of MMPs between different groups were compared using the non-parametric Mann-Whitney U-test or the Kruskal-Wallis test. Multivariate logistic regression analysis was conducted to control ORs for confounding factors. Demonstration of numeric data was done by Mean ± standard deviation (SD) and nominal data was presented as numbers and percentage. GraphPad PRISM software v.8.00 (GraphPad Software, Inc., San Diego, CA, USA) was used for data analysis and designing graphs.

Results

Allele and genotype frequencies in COVID-19 patients and healthy controls

Distribution of genotypes for all three SNPs did not deviate from HWE in the control group (Table 2). The genetic comparisons in the MMP9 gene rs3918242 and MMP3 gene rs3025058 SNP was associated with risk of COVID-19, while MMP2 gene rs243865 did not show any significant difference.

It was observed that frequency of the T allele of MMP9 gene rs3918242 was higher in the COVID-19 patients compared to the controls (19.2% vs. 13.4%); hence the T allele was significantly associated with a 1.53-times increased risk of COVID-19 (OR = 1.53, 95%CI = 1.09–2.15; P = 0.013). Additionally, the dominant genetic comparison (TT + CT vs. CC) was significantly associated with a 1.51-times increased risk of COVID-19 (OR = 1.51, 95%CI = 1.02–2.24; P = 0.037). The TT genotype was highly seen in the COVID-19 group and increased COVID-19 risk 2.40 times, even though it was not statistically significant (OR = 2.40, 95%CI = 0.95–6.05; P = 0.061). The recessive TT vs. CT + CC model was observed to be insignificantly associated with a 2.21 times increased COVID-19 risk (OR = 2.21, 95%CI = 0.88–5.53; P = 0.088). The CT genotype did not have statistically significant association with COVID-19 risk, even though it caused a 1.40-times increased
COVID-19 risk (OR = 1.40, 95% CI = 0.92–2.12; P = 0.113; Table 2).

The minor G allele of MMP3 gene rs3025058 SNP had a statistically significant and strong association with a 1.54-times increased risk of COVID-19 (OR = 1.54, 95% CI = 1.13–2.11; P = 0.006). Interestingly, the GG genotype was significantly associated with a 7.78-times higher risk of COVID-19 (OR = 7.78, 95% CI = 2.27–26.6; P = 0.001), which was statistically stronger association. Moreover, the dominant genetic model (GG vs. GC + CC) had statistically significant association with a 7.55-times increased risk of COVID-19 (OR = 7.55, 95% CI = 2.22–25.6; P = 0.0012). The GC genotype (OR = 1.09, 95% CI = 0.74–1.61) had a statistically significant association with slightly increased COVID-19 risk (Table 2).

For MMP2 gene rs243865, it was detected that the T allele (OR = 1.04), TT genotype (OR = 1.34), dominant TT vs. CT + CC model (OR = 1.35), and recessive TT + CT vs. CC model (OR = 1.01) had statistically insignificant association with a slight increased risk of COVID-19. However, the CT genotype was insignificantly associated with decreased COVID-19 risk (OR = 0.98; Table 2).

### Table 2: Allele and genotype frequencies of MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms in COVID-19 patients and healthy controls and related association analyses

| SNP              | Allele /Genotype | COVID-19 (n = 500) | Healthy controls (n = 500) | OR (95% CI) | P     |
|------------------|------------------|--------------------|---------------------------|-------------|-------|
| **MMP9rs3918242**| T vs. C          | 192 (19.2)         | 134 (13.4)                | 1.53 (1.09–2.15) | 0.013 |
|                  | C (Reference)    | 808 (80.8)         | 866 (86.6)                | -           | -     |
|                  | TT vs. CC        | 30 (6)             | 14 (2.8)                  | 2.40 (0.95–6.05) | 0.061 |
|                  | CT vs. CC        | 132 (26.4)         | 106 (21.2)                | 1.40 (0.92–2.12) | 0.113 |
|                  | TT vs. CT + CC   | 30 (6)             | 14 (2.8)                  | 2.21 (0.88–5.53) | 0.088 |
|                  | TT + CT vs. CC   | 162 (32.4)         | 120 (24)                  | 1.51 (1.02–2.24) | 0.037 |
|                  | CC (Reference)   | 338 (67.6)         | 380 (76)                  | -           | -     |
| **HWE**          |                  |                    |                           |             |       |
| **MMP3rs3025058**| G vs. C          | 238 (23.8)         | 168 (16.8)                | 1.54 (1.13–2.11) | 0.006 |
|                  | C (Reference)    | 762 (76.2)         | 832 (83.2)                | -           | -     |
|                  | GG vs. CC        | 42 (8.4)           | 6 (1.2)                   | 7.78 (2.27–26.6) | 0.001 |
|                  | GC vs. CC        | 154 (30.8)         | 156 (31.2)                | 1.09 (0.74–1.61) | 0.634 |
|                  | GG vs. GC + CC   | 42 (8.4)           | 6 (1.2)                   | 7.55 (2.22–25.6) | 0.0012 |
|                  | GG + GC vs. CC   | 196 (39.2)         | 162 (32.47)               | 1.34 (0.92–1.94) | 0.113 |
|                  | CC (Reference)   | 304 (60.8)         | 338 (67.6)                | -           | -     |
| **HWE**          |                  |                    |                           |             |       |
| **MMP2rs243865** | T vs. C          | 212 (21.2)         | 204 (20.4)                | 1.04 (0.77–1.42) | 0.755 |
|                  | C (Reference)    | 788 (78.8)         | 796 (79.6)                | -           | -     |
|                  | TT vs. CC        | 24 (4.8)           | 18 (3.6)                  | 1.34 (0.54–3.27) | 0.518 |
|                  | CT vs. CC        | 164 (32.8)         | 168 (33.6)                | 0.98 (0.67–1.43) | 0.926 |
|                  | TT vs. CT + CC   | 24 (4.8)           | 8 (3.6)                   | 1.35 (0.55–3.26) | 0.505 |
|                  | TT + CT vs. CC   | 188 (37.6)         | 186 (37.2)                | 1.01 (0.70–1.46) | 0.926 |
|                  | CC (Reference)   | 312 (62.4)         | 314 (62.8)                | -           | -     |
| **HWE**          |                  |                    |                           |             |       |

SNP, Single nucleotide polymorphism; MMP, Matrix metalloproteinase; COVID-19, Coronavirus disease 2019; OR, Odds ratio; 95% CI, 95% Confidence interval; HWE, Hardy-Weinberg equilibrium.

Table 3 shows the allele and genotype frequencies of MMP9 gene rs3918242, MMP3 gene rs3025058 SNP, and MMP2 gene rs243865 in COVID-19 patients with neurologic syndrome and healthy controls.

The T allele of MMP9 gene rs3918242 was highly represented in COVID-19 patients with neurologic syndrome in comparison to controls (22.2% vs. 13.4%). The analysis indicated that the T allele had statistically significant (but marginal) association with a 1.84-times increased risk of COVID-19 with neurologic syndrome (OR = 1.84, 95% CI = 1.00–3.40; P = 0.049). Even though it was not statistically significant and the CI was wide, the TT genotype was associated with a 3.54 times increased risk of COVID-19 with neurologic syndrome (OR = 3.54, 95% CI = 0.85–14.6; P = 0.081). The CT genotype had also higher expression in the COVID-19 with neurologic syndrome and was significantly associated with a 1.55-times increased risk of the COVID-19 with neurologic syndrome (OR = 1.55, 95% CI = 0.69–3.47; P = 0.278). The analysis also revealed that both dominant TT vs. CT + CC (OR = 3.15) and recessive TT + CT vs. CC (OR = 1.78) models had statistically
insignificant association with increased risk of COVID-19 with neurologic syndrome.

For MMP3 gene rs3025058, it was seen that the minor G allele was associated with a 2.23-times increased risk of COVID-19 with neurologic syndrome (OR = 2.23, 95%CI = 1.34–4.02; P = 0.002). As well, it was detected that GG genotype had statistically significant association with a strong 13.25-times increased risk of COVID-19 with neurologic syndrome (OR = 13.25, 95%CI = 2.73–64.2; P = 0.001). A statistically significant association was found between the dominant (OR = 2.23, 95%CI = 1.15–4.72; P = 0.018) and the recessive (OR = 10.29, 95%CI = 2.20–48.1; P = 0.003) models and increased (2.23-times and 10.29-times, respectively) risk of COVID-19 with neurologic syndrome (Table 3).

Even though all genetic comparisons for MMP2 gene rs243865 were not statistically significant, they were associated with an increased risk (T allele OR = 1.11, TT genotype OR = 1.58, CT genotype OR = 1.01, dominant model OR = 1.57, recessive model OR = 1.07) of COVID-19 with neurologic syndrome.

Regression analysis

The multivariate logistic regression analysis was performed to adjust ORs of statistically significant comparisons in MMP SNPs for potential confounding factors. It was observed that for the MMP9 rs3918242 SNP in the TT vs. CT vs. CC model, the ORs were still statistically significant after controlling for the potential confounders, including Age, Sex, Fever, Cough, Dyspnea, Sputum, Vomiting/diarrhea, Delirium, Encephalitis, and Headache. As such, ORs were still statistically significant for MMP3 rs3025058 SNP in both GG vs. CC and GG vs. GC + CC models after controlling for the confounders (Table 4).

Serum levels of MMPs

The serum level of MMP-9 was significantly higher in COVID-19 cases (612.32 ± 110.54 ng/ml) compared with the healthy controls (412.25 ± 8.74 ng/ml; P = 0.009; Fig. 1A). Additionally, serum MMP-3 level was significantly higher in COVID-19 subjects (45.25 ± 12.44 ng/ml) in comparison to the healthy controls (27.44 ± 8.74 ng/ml; P = 0.0005; Fig. 1B). There was no statistically significant difference in the serum level of MMP-2 between COVID-19 cases and healthy controls (Fig. 1C).
(Fig. 2.C) had different levels among COVID-19 patients with different three genotypes for MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms, respectively. Additionally, no significant differences were observed in serum levels of MMP-9 (Fig. 2.D), MMP-3 (Fig. 2.E), and MMP-2 (Fig. 2.F) among COVID-19 patients with neurologic syndrome with three different genotypes for MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms, respectively.

**Discussion**

The major target tissue of SARS-CoV-2 is lungs but other tissues like heart and kidney might be involved [1, 2]. Whereas most of the patients with COVID-19 experience a mild form of the disease, the occurrence of acute respiratory distress syndrome (ARDS) is also frequent [20]. In the severe forms of the disease, uncontrolled production of inflammatory cytokines leads to cytokine storm, which
Regulate proinflammatory cytokines like interleukin (IL)-1β and TNF-α [23]. Several reports indicate that inflammation and dysregulated immune responses like cytokine storm and related inflammatory mediators (such as IL-1β, IL-6 and TNF-α) contribute to the pathology of COVID-19 [21]. A study by Shi et al. revealed that MMP-3 level was higher in the serum of COVID-19 patients that was correlated with serum levels of IL-1β and IL-6 [9]. As a result, MMPs might contribute to the inflammatory state in COVID-19 patients and worsen the clinical presentations of the suffering cases.

Inflammatory mediators are involved in the stimulation of MMP-3 secretion form endothelial cells and fibroblasts. On the other hand, MMP-3 can also target, and hence regulate, proinflammatory cytokines like interleukin (IL)-1β and TNF-α [23]. Several reports indicate that inflammation and dysregulated immune responses like cytokine storm and related inflammatory mediators (such as IL-1β, IL-6 and TNF-α) contribute to the pathology of COVID-19 [21]. A study by Shi et al. revealed that MMP-3 level was higher in the serum of COVID-19 patients that was correlated with serum levels of IL-1β and IL-6 [9]. As a result, MMPs might contribute to the inflammatory state in COVID-19 patients and worsen the clinical presentations of the suffering cases.

Fig. 1 Bar charts demonstrate the serum concentration of MMP-9, MMP-3, and MMP-2 in the COVID-19 subjects and healthy controls (A, B, C). The comparison of the serum levels of MMP-9, MMP-3, and MMP-2 in the COVID-19 patients with neurologic syndrome (NS) compared with healthy controls (D, E, F). The mean comparisons were done by statistical test of Mann-Whitney’s U test (** shows $P<0.01$, *** shows $P<0.001$; ns, non-significant).
It was indicated that SARS-CoV-2 exerts Transmembrane serine protease 2 (TMPRSS2) to prime S protein that facilitates binding to ACE2 and entry to the target cells. Additionally, a TMPRSS2 inhibitor was suggested to block the virus entry and might be used as a therapeutic compound in the COVID-19 patients [24]. Additionally, it was reported that zinc metalloproteases like MMPs might contribute to the cell-cell fusion and entry of coronavirus [25]. As a consequence, MMPs are probably involved in facilitating the entry of virus to host cells. Our experiments also indicated higher serum levels of MMP-9 and MMP-3 in COVID-19 patients. Hence, it is worthy to explore for the potential treatment options in COVID-19 patients through investigating compounds that inhibit the function of MMPs.

Studies have established that rs3918242 as the functional SNP in the promoter region MMP9 gene affect the transcriptional level of this gene [26, 27]. Additionally, in vitro studies revealed that the C–1562 T SNP (rs3918242) is involved in suppressing the binding of nuclear repressor protein to the promoter region in which this SNP is harbored, resulting in promotion of the expression of MMP9 [28]. At the position –1612/–1617 upstream of the transcription start site of MMP3 gene, insertion of adenosine into the promoter region leads to constitution of a polymonomeric series of
six adenosines (which is called allele 6 A), whereas the wild type form occurs with five adenosines (named as allele 5 A). Studies have demonstrated that the presence of the 6 A allele was associated with the downmodulation MMP3 expression [29]. Here we hypothesized that genetic polymorphisms in the MMP genes might alter the protein levels of MMPs and contribute to the development of COVID-19 disease. At first, we detected that the T allele of MMP9 gene rs3918242 SNP (OR = 1.84) as well as the G allele (5 A) of MMP3 gene rs3025058 (OR = 2.3) were associated with increased risk of COVID-19. Moreover, the serum levels of both MMP-9 and MMP-3 were higher in the serum levels of COVID-19 patients. However, it was observed that none of the MMP-9 and MMP-3 had different levels among COVID-19 patients with different three genotypes for MMP9 rs3918242 and MMP3 rs3025058, respectively. As a result, it seems that genetic polymorphisms might not be involved in the regulation of the MMP levels in the COVID-19 patients. It should, however, be noted that there are several genetic polymorphisms in each of these genes that might control the transcription of MMPs that were not evaluated in this study.

It has been reported that MMP-9 play a role in the degradation of the BBB in multiple sclerosis (MS), which is a neurodegenerative disorder [8, 30]. MMP-9 degrades the ECM and myelin basic protein (MBP) in MS patients, resulting in infiltration of the inflammatory immune cells into the CNS [31–34]. It seems that increased permeability of BBB by MMP-9 alongside with promoted expression of ICAM-1 (which mediates the recruitment of immune cells through endothelium) on the endothelial cells by TNF-α facilitates the migration of virus-infected monocytes to the CSF [10]. Additionally, reports have shown the presence of SARS-CoV-2 nucleic acid in the CSF samples of COVID-19 patients [4]. Furthermore, increased number of immune cells in the CSF of COVID-19 cases was reported [35]. Additionally, level of MMP-10 in the spinal fluid was correlated with the level of neurologic dysfunction in COVID-19 cases [36]. Our previous research also revealed that monocytes in the CSF of COVID-19 patients with neurological syndrome secrets high levels of MMP-2, MMP-3, MMP-9, and MMP-12 that might result in disruption of blood-CSF barrier, which in turn might facilitate recruitment of more immunoinflammatory cells into CNS, culminating in presentation of neurological symptoms in the COVID-19 subjects [37].

Here we also observed that the levels of MMP-9 and MMP-3 were higher in the serum samples from COVID-19 cases with neurologic syndrome in comparison to the controls. We also detected significant association of MMP9 gene rs3918242 and MMP3 gene rs3025058 polymorphisms with the risk of COVID-19 with neurologic syndrome. Nonetheless, there were no significant differences in the levels of MMP-9 and MMP-3 in COVID-19 cases with neurologic syndrome harboring three genotypes for MMP9 rs3918242 and MMP3 rs3025058, respectively. Therefore, at least we can prematurely assert that MMP9 rs3918242 and MMP3 rs3025058 might not be involved in regulating the MMP-9 and MMP-3 in COVID-19 cases with neurologic manifestations. Probably other genetic markers in these gens as well as other regulatory mechanisms play a role in the modulation of MMPs in COVID-19 subjects with neurologic symptoms.

Considering all the facts, our attempt to disclose the probable implication of MMPs in risk of COVID-19 revealed that MMP9 gene rs3918242 and MMP3 gene rs3025058 SNP, but not MMP2 gene rs24386s5, was associated significantly with increased risk of the disease. Additionally, both these SNPs were associated with susceptibility to COVID-19 with neurologic symptoms. Although levels of MMP-9 and MMP-3 was higher in the serum of COVID-19 cases as well as COVID-19 individuals with neurologic syndrome, the related genetic polymorphisms might not be involved in the regulation of corresponding MMPs. Hence, we need to be armed with further investigation to understand the involvement of MMP genetic polymorphisms in raising neurologic complications in the COVID-19 cases.

Acknowledgements The authors are grateful of the patients for their contribution in this study.

Author contribution Samaneh Ramezani; Performed experiments, prepared the draft of the paper, and read the manuscript critically. Fateh Ezattifar; Performed experiments, prepared the draft of the paper, and read the manuscript critically. Taherch Hojjatipour; Participated in experiments and drafting the paper, and read the manuscript critically. Maryam Hemmatzadeh; Participated in experiments and drafting the paper, and read the manuscript critically. Arezoo Gowhari Shabagh; Participated in experiments and drafting the paper, and read the manuscript critically. Jamshid Gholizadeh Navashenaj; Participated in experiments and drafting the paper, and read the manuscript critically. Saeed Aslani; Participated in experiments and drafting the paper, performed statistical analysis, and read the manuscript critically. Navid Shomali; Participated in experiments and drafting the paper, and read the manuscript critically. Mohsen Arabi; Participated in drafting the paper and read the manuscript critically. Farhad Babaie; Participated in drafting the paper and read the manuscript critically. Farhad Jadidi-Niaragh; Participated in drafting the paper and read the manuscript critically. Ramin Hosseinzadeh; Participated in drafting the paper and read the manuscript critically. Fahimeh Feizisani; Participated in drafting the paper and read the manuscript critically. Sara Khodayar; Participated in drafting the paper and read the manuscript critically. Roghaiyeh Safari; Developed the main idea, designed the work, interpreted the experiments, and read the manuscript critically. Hamed Mohammad; Developed the main idea, designed the work, interpreted the experiments, and read the manuscript critically.

Funding This study was financially supported by a grant from the Alborz University of Medical Sciences, Karaj, Iran (Grant No. 99-4209).

Data Availability All data generated or analyzed during this study are included in this published article.
The study protocol was approved from the local Ethical Review committee located in Alborz University of Medical Sciences (Permission No. IR.ABZUMS.REC.1399.340) and written informed consent form was taken by all subjects.

Research involving human subjects and/or animals Research carried out here were in compliance with the Helsinki Declaration. The protocol of this study was approved by the Human Research Ethics Committee from the Alborz University of Medical Sciences, Karaj, Iran (Permission No. IR.ABZUMS.REC.1399.340). Written informed consent forms were obtained from patients and healthy controls before blood taking.

Conflict of interest The authors declare that they have no conflicting interests.

References

1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273
2. Turner AJ, Hiscox JA, Hooper NM (2004) ACE2: from vaso- peptidease to SARS virus receptor. Trends Pharmacol Sci 25(6):291–294
3. Helms J, Kremer S, Merdji H, Clerc-Jehl R, Schenck M, Kummerlen C et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382(23):2268–2270
4. Puelles VG, Lütgehutmann M, Lindenmeyer MT, Sperhake JP, Talbot PJ (2014) Human coronaviruses: viral and cellular factors influencing/deletion polymorphism in its promoter region. Cancer Res 75(17):4225–4227
5. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Assani S, Imani D, Razi B et al (2020) Matrix metalloproteinases-9 (MMP-9) gene family polymorphisms and risk of Coronavirus Artery Disease (CAD): a systematic review and meta-analysis. BMC Cardiovasc Disord 20(1):1232. https://doi.org/10.1186/s12872-020-01510-4
6. Singh H, Nain S, Krishnaraj A, Lata S, Dhole TN (2019) Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. Gene 698:41–49. https://doi.org/10.1016/j.gene.2019.02.057
7. Herbster S, Paladino A, de Freitas S, Boccanio E (2018) Alterations in the expression and activity of extracellular matrix components in HPV-associated infections and diseases. Clinics (Sao Paulo, Brazil) 73 (suppl 1):e551s. https://doi.org/10.6061/clinics/2018/e551s
8. Mohammadhosayni M, Khosrojerdi A, Lorian K, Aslani S, Imani D, Razi B et al (2020) Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis. BMC Neuro 20(1):218. https://doi.org/10.1186/s12883-020-01804-2
9. Behl T, Kaur G, Sehgal A, Bhardwaj S, Singh S, Buhas C et al (2021) Monofaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeu- tic Perspectives. Int J Mol Sci 22(3). https://doi.org/10.3390/ijms22031413
10. La Russa A, Cittadella R, De Marco EV, Valentino P, Andreoli V, Trecroci F et al (2010) Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroinmunol 225(1–2):175–179
11. Nissinen L, Kähäri V-M (2014) Matrix metalloproteinases in tumor metastasis and angiogenesis. J Bio- chem Mol Biol 36(1):128–137
12. Shapiro SD (1998) Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 10(5):602–608
13. Bhardwaj S, Singh S, Singh S, Buhas C et al (2021) Monofaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeu- tic Perspectives. Int J Mol Sci 22(3). https://doi.org/10.3390/ijms22031413
14. Yong VW, Zabad RK, Agrawal S, DaSilva AG, Metz LM (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 259(1–2):79–84
15. Hassanzadeh-Makoui R, Razi B, Aslani S, Imani D, Tabae SS (2020) The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronavirus Artery Disease (CAD): a systematic review and meta-analysis. BMC Cardiovasc Disord 20(1):1232. https://doi.org/10.1186/s12872-020-01510-4
16. Singh H, Nain S, Krishnaraj A, Lata S, Dhole TN (2019) Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. Gene 698:41–49. https://doi.org/10.1016/j.gene.2019.02.057
17. Herbster S, Paladino A, de Freitas S, Boccanco E (2018) Alterations in the expression and activity of extracellular matrix components in HPV-associated infections and diseases. Clinics (Sao Paulo, Brazil) 73 (suppl 1):e551s. https://doi.org/10.6061/clinics/2018/e551s
18. Mohammadhosayni M, Khosrojerdi A, Lorian K, Aslani S, Imani D, Razi B et al (2020) Matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of multiple sclerosis: systematic review and meta-analysis. BMC Neuro 20(1):218. https://doi.org/10.1186/s12883-020-01804-2
19. Behl T, Kaur G, Sehgal A, Bhardwaj S, Singh S, Buhas C et al (2021) Monofaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeu- tic Perspectives. Int J Mol Sci 22(3). https://doi.org/10.3390/ijms22031413
20. Han S, Mallampalli RK (2015) The acute respiratory dis- tress syndrome: from mechanism to translation. J Immunol 194(3):855–860
21. Ebrahimi N, Aslani S, Babaie F, Hemmatzaddeh M, Hosseinzeadeh R, Joneidi Z et al (2020) Recent findings on the Coronavirus disease 2019 (COVID-19): immunopathogenesis and immunomanares. International immunopharmacology:107082
22. Yamashita CM, Cybulskie C, Milos S, Zuo YY, McCaig LA, Veldhuizen RA (2016) The effect of matrix metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model of acute lung injury. Can J Physiol Pharmacol 94(6):599–602
23. Fengxian C, Shichen S, Wang S, Wang H, Li G, Fan J et al (2018) Evaluation of matrix metalloproteinases (MMPs) expression in the lung tissue of patients with COVID-19. Int J Mol Sci 19(11):2592
24. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271–280e278.
25. Phillips JM, Gallagher T, Weiss SR (2017) Neurovirological murine coronavirus JHM. SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion.Journal of virology91 (8)
26. Hernandez J, Bruch A, Lapidus J, Kurilla R,odler J Freitas J, Rocha A et al (2015) The acute respiratory dis- tress syndrome: from mechanism to translation. J Immunol 194(3):855–860
27. Singh H, Nain S, Krishnaraj A, Lata S, Dhole TN (2019) Genetic variation of matrix metalloproteinase enzyme in HIV-associated neurocognitive disorder. Gene 698:41–49. https://doi.org/10.1016/j.gene.2019.02.057
28. Phillips JM, Gallagher T, Weiss SR (2017) Neurovirological murine coronavirus JHM. SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion.Journal of virology91 (8)
29. Gomes J, Freitas J, Rocha A et al (2015) The acute respiratory dis- tress syndrome: from mechanism to translation. J Immunol 194(3):855–860
30. La Russa A, Cittadella R, De Marco EV, Valentino P, Andreoli V, Trecroci F et al (2010) Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroinmunol 225(1–2):175–179
31. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S (1999) Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12. 2–131. Hum Genet 105(5):418–423
29. Souslova V, Townsend PA, Mann J, van der Loos CM, Motterle A, D’Acquisto F et al (2010) Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFκB. PLoS ONE 5(3):e9902

30. Waubant E (2006) Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 22(4):235–244

31. Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling.FASEB J 5(8):2145–2154

32. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201(3):223–226

33. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G (1993) Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 36(4):432–440

34. Proost P, Vandamme J, Opdenakker G (1993) Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 192(3):1175–1181

35. Neumann B, Schmidbauer ML, Dimitriadis K, Otto S, Knier B, Niesen W-D et al (2020) Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. Journal of the neurological sciences 418

36. Remsik J, Wilcox JA, Babady NE, McMillan TA, Vachha BA, Halpern NA et al (2021) Inflammatory leptomeningeal cytokines mediate COVID-19 neurologic symptoms in cancer patients. Cancer Cell 39(2):276–283 e273

37. Mohammadhosayni M, Mohammadi FS, Ezzatifar F, Gorabi AM, Khosrojerdi A, Aslani S et al (2021) Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019. Int Immunopharmacol 100:108076

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Samaneh Ramezani1, Fatemeh Ezzatifar2,3, Tahereh Hojjatipour4, Maryam Hemmatzadeh5, Arezoo Gowhari Shabgah6, Jamshid Ghohizadeh Navashenaq7, Saeed Aslani8, Navid Shomalii5, Mohsen Arabi9, Farhad Babaie10, Farhad Jadidi-Niaragh11,12, Ramin Hosseinzadeh8, Fahimeh Feizisani13, Sara Khodayar14, Roghaiyeh Safari15,16, Hamed Mohammadi14,17